[2] Since 1999, Thomas has served as a visiting scholar at the Congressional Research Service.
He has served as a visiting scholar at the Max Planck Institute for Intellectual Property and Competition Law in Munich, Germany, and the Institute of Intellectual Property in Tokyo, Japan.
[2] The 2005 first edition of his Pharmaceutical Patent Law was well-reviewed by Dennis Crouch of Patently-O, who described it as "an excellent treatise that will be very well regarded for years to come" and "surprisingly readable".
[3] In 2019, Thomas suggested that patent "march-in rights", which permit the U.S. government to force licensure of certain patents, "might make drugmakers pause" before exacting excessive prices for their products,[4] a view for which Thomas was criticized by Joseph Allen of IPWatchdog, who asserted that in a previous Congressional Research Service report, Thomas appeared to assert that such use of march-in rights would require further Congressional action.
[5] Thomas has authored and co-authored many books, primarily in the field of intellectual property.